Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Mobico CEO steps down as profits disappoint

(Sharecast News) - Troubled transport operator Mobico said chief executive Ignacio Garat would be stepping down, days after the company issued a profit alert that sent its shares plunging by more than 40%. Guarat will step down on Wednesday with Phil White, chair designate, taking on the role of interim-executive chair from May 1.

Mobico also reported annual adjusted operating profit of £187.7m - just above the lower end of the £185m - £205m range of analyst expectations.

On a reported basis, operating losses widened to £520m from £43m and pre-tax losses were £609m from £120m, due to goodwill impairments, a write-off of deferred tax assets in UK and North America and an increased onerous contract provision in German Rail.

Shares in the firm, formerly known as National Express, hit the skids last week on the news. The stock, which was at 467p just before the Covid pandemic struck, was languishing at 33.5p on Monday with a market capitalisation of around £206m compared with £2.4bn at the end of December 2019.

The news completely overshadowed the sale of its North America school bus business to I Squared Capital for up to $608m (£457m), from which Mobico expects net proceeds of up to £385m - less than markets expected.

"In FY25, on a continuing business basis, the group expects to make continued revenue and adjusted operating profit progress, with further strong performance from ALSA and ongoing growth in WeDriveU, alongside further recovery in UK & Germany," the company said on Tuesday.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.